Mark Cacciamani, MD
Family Medicine · Salt Lake City, UTNPI 1063500163
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,691 of the $42,653 with a category attached, or 93.1%. AbbVie accounts for 99.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $26,184 and has fallen 98.4% since, to $423 in 2025. Among family medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $292.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$42K
- Galderma Laboratories, L.p.$238
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$38
- Acadia Pharmaceuticals Inc$21
What the payments were for
- Speaking & faculty fees$39,69193%
- Food & beverage$2,9627%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 136 | $42,356 |
| Galderma Laboratories, L.p. | 7 | $238 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$362
How this compares
$42,653 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 13 | $47,672 |
| AristadaAripiprazole Lauroxil | 12 | $39,199 |
| OzempicSemaglutide | 14 | $15,691 |
| EliquisApixaban | 19 | $12,753 |
| MyrbetriqMirabegron | 14 | $6,758 |
| Ziprasidone Hcl | 15 | $3,382 |
| Aripiprazole | 49 | $3,144 |
| Omeprazole | 131 | $3,010 |
| Atorvastatin Calcium | 135 | $2,408 |
| Fluticasone Propionate | 62 | $2,004 |
| Risperidone | 76 | $1,867 |
| Gabapentin | 46 | $1,845 |
| Topiramate | 49 | $1,834 |
| Diclofenac Potassium | 20 | $1,750 |
| Trazodone Hcl | 113 | $1,623 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Salt Lake City
- Kirk OdonnellSalt Lake City$23K
- Jared ProbstSalt Lake City$15K
- Derek MuseSalt Lake City$14K
- Kristen RomoSalt Lake City$13K
- Julie DaySalt Lake City$11K
- Mark JohnsonSalt Lake City$8K
- Stephen ColemanSalt Lake City$8K
- David LarsenSalt Lake City$8K
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.